Therefore, we hypothesized that the use of NETs inhibitors or anti‐IL‐17A antibodies to suppress IL‐17A may disrupt this loop, thereby alleviating apical periodontitis and bone destruction. The gene discussed is IL17A; the disease is periapical periodontitis.